The Krabbe Disease Treatment Market reached approximately USD 262 25 million in 2025 and is expected to reach nearly USD 786 45 million by 2033 growing at a CAGR of 16 8 during the forecast period from 2026 to 2033 ... Regional Insights: -North America: 42.8% (Largest share, supported by advanced healthcare infrastructure, comprehensive newborn screening programs, specialized treatment centers, and strong clinical research activity). -Europe: 28.6% (Second-largest share, driven by well-established healthcare systems, rare disease policies, collaborative research networks, and access to specialized therapies). Press release - DataM Intelligence 4 Market Research LLP - Krabbe Disease Treatment Market to Reach USD 786.45 Million as U.S. Gene Therapy Clinical Trials Accelerate Through 2033 - published on openPR.com

Recent molecular dynamics simulations have analyzed four GALC variants linked to Krabbe disease, providing insights into their structural impacts. This research enhances understanding of the disease mechanisms and may inform future therapeutic strategies.

A recent study provides clinical and molecular insights into Krabbe disease among Iranian patients, contributing to the understanding of this rare genetic disorder. The case report highlights unique characteristics and expands the existing literature on Krabbe disease.

A rare case study highlights brachial plexopathy in juvenile-onset Krabbe disease, contributing to the understanding of this condition. This discovery may inform future research and clinical approaches to managing symptoms in affected patients.